Navigation Links
Organovo To List Common Stock On New York Stock Exchange MKT
Date:7/9/2013

SAN DIEGO, July 9, 2013 /PRNewswire/ --  Organovo Holdings, Inc. (OTCQX: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on July 11, 2013.  The Company will continue to trade under the symbol "ONVO" but will withdraw its shares from listing on the OTC QX concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.

"Trading on the New York Stock Exchange is an important milestone for Organovo and will be valuable to our business and shareholders. Our decision to move to the NYSE MKT was based on a firm belief that the exchange offers the best set of conditions for Organovo's success, and thus the best opportunity to add value for our shareholders," said Keith Murphy, President and CEO of Organovo Holdings, Inc..  "We found NYSE to have made an unparalleled commitment to providing a fertile platform for growth to early stage biotechnology companies, and we look forward to a great future on the exchange."

NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies.  The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility.  Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value.  In addition, NYSE MKT-listed companies gain access to the brand v
'/>"/>

SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
3. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Organovo Announces Relocation and Commencement of Operations at Larger Facility
6. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
7. Organovo To Present At Lazard Healthcare Conference
8. Organovo Reports Q3 2012 Financial Results, Provides Business Update
9. Organovo Holdings, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
10. Organovo Partners With ZenBio to Create 3D Tissue Models
11. Organovo to Present at the 12th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology ... cancer immunotherapy treatment targeting HPV-16, has generated strong ... Currently, pre-cervical cancer is treated by surgical ... simple and effective non-surgical alternative. Results show that ... (T-cells) to recognize, target, and kill precancerous and ...
(Date:5/28/2015)... The Fertility Centers of New England is proud to ... on a new and expanded role as Medical Director. ... oversight and quality assurance for the practice. , “We ... of experienced reproductive endocrinologists,” said Fertility Centers of New ... expertise and compassionate, individualized care have helped set FCNE ...
(Date:5/28/2015)... Rochelle, Virginia (PRWEB) May 28, 2015 ... Partners LLC announced today that Roger L. Williams, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:5/27/2015)... 26, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Molecular ... to their offering. This report ... that will play an important role in ... forensics and biological warfare in the 21st ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3
... Osaka, Japan, for the Bio Japan 2006 conference as ... of times over the years about both the Japanese pharma and ... few years and I'm looking forward to getting up to speed ... reminder: Chicago and Osaka are sister cities and my last visit ...
... EraGen Biosciences , a Madison-based developer of diagnostic ... outline its product development plans. , ,Irene Hrusovsky, CEO ... of the company to attendees of the Mid-America ... of ZyStor Therapeutics, Inc. , a Milwaukee-based developer ...
... other TV news broadcasts, the accusation that Hewlett ... of directors was revealed. Because she was afraid that ... Patricia Dunn, unilaterally authorized a project headed up by ... personal phone records of board members. www.msnbc.msn.com/id/14687677/site/newsweek ...
Cached Biology Technology:Chinese pharma-biotech dragon rears its head 2Chinese pharma-biotech dragon rears its head 3Chinese pharma-biotech dragon rears its head 4Chinese pharma-biotech dragon rears its head 5Chinese pharma-biotech dragon rears its head 6EraGen set to highlight diagnostic products at BIO 2Compliance at HP - Pretexting paranoia 2Compliance at HP - Pretexting paranoia 3Compliance at HP - Pretexting paranoia 4Compliance at HP - Pretexting paranoia 5
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Yamanaka MD, PhD, of Kyoto University and the Gladstone ... forward in improving the possibilities for the practical application ... Dr. Yamanaka had shown that adult cells can be ... oncogene as one of the four genes required to ...
... Jim Doyle today announced a historic collaboration between ... care leading to health care that proactively addresses ... research effort among the Marshfield Clinic, Medical College ... Medicine and Public Health (UWSMPH) and UW-Milwaukee (UWM). ...
... one of the most thoroughly studied organisms in the ... understanding variation in physiology, behavior, life history and morphology ... On biological levels from molecular and genetic to developmental ... it has proven far more complex than even imagined. ...
Cached Biology News:Yamanaka eliminates viral vector in stem cell reprogramming 2Governor Doyle announces historic genomic research collaboration 2Fitness in a changing world 2Fitness in a changing world 3
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... #27295 has improved stability and convenience from the ... only has overcome this problem but also produced ... changed the formulation of HRP conjugated antibody from ... this change, the stability of the conjugate has ...
Biology Products: